Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study

BACKGROUND: We designed this randomised, open-label, parallel group, multi-centre study to investigate the efficacy and safety of glycopyrronium/formoterol, a long-acting muscarinic antagonist/long-acting β2-agonist fixed dose combination, delivered through a dry powder inhaler (DPI) in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvi, Sundeep, Kumar, Anand, Agrawal, Sumit, Leuva, Amritlal, Shukla, Vineet Kumar, Deshpande, Shrikant Vishnu, Balamurugan, Santhalingam, Singh, Ajit, Tikkiwal, Sharad, Gupta, Sandeep K., Singh, Bhanu Pratap, Lopez, Meena, Sawant, Sandesh, Vaidya, Abhijit, Gogtay, Jaideep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623852/
https://www.ncbi.nlm.nih.gov/pubmed/36629200
http://dx.doi.org/10.4103/lungindia.lungindia_92_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623852/
https://www.ncbi.nlm.nih.gov/pubmed/36629200
http://dx.doi.org/10.4103/lungindia.lungindia_92_22

Ejemplares similares